Hostname: page-component-78c5997874-dh8gc Total loading time: 0 Render date: 2024-11-19T22:45:11.490Z Has data issue: false hasContentIssue false
  • English
  • Français

Plasma levels of endothelial cell-specific molecule-1 and pentraxin-3 in idiopathic sudden sensorineural hearing loss

Published online by Cambridge University Press:  29 October 2018

F Gündoğan ,
A Bayram ,
M Kalkan  and
İ Özcan
F Gündoğan
Affiliation:
Department of ENT, Boğazlıyan State Hospital, Kayseri, Turkey
A Bayram*
Affiliation:
Department of ENT, Kayseri Training and Research Hospital, Turkey
M Kalkan
Affiliation:
Department of ENT, Kayseri Training and Research Hospital, Turkey
İ Özcan
Affiliation:
Department of ENT, Kayseri Training and Research Hospital, Turkey
*
Author for correspondence: Dr Ali Bayram, Kayseri Training and Research Hospital, Sanayi Mah. Atatürk Bulvarı Hastane Cad. No: 78, Kayseri 38010, Turkey E-mail: [email protected] Fax: +90 352 3207313
Get access Rights & Permissions [Opens in a new window]

Abstract

Objectives

To evaluate the plasma levels of endothelial cell-specific molecule-1 (ESM-1) and pentraxin-3 (PTX-3) in patients with idiopathic sudden sensorineural hearing loss, and to compare the pre- and post-treatment levels in patients responsive and non-responsive to therapy.

Methods

The study included 108 subjects: 51 with idiopathic sudden sensorineural hearing loss and 57 controls. For ESM-1 and PTX-3 analyses, blood samples were collected before and three months after treatment initiation in the idiopathic sudden sensorineural hearing loss group and once for the control group. Treatment response was evaluated three months after therapy initiation with pure tone audiometry, and the patients were divided into two groups: responsive and non-responsive to treatment.

Results

Serum ESM-1 levels were significantly higher in the idiopathic sudden sensorineural hearing loss group than the control group, whereas the difference was not significant for PTX-3. In the responsive and non-responsive groups, ESM-1 and PTX-3 levels were not statistically different before and after treatment.

Conclusion

To our knowledge, this is the first study investigating plasma ESM-1 and PTX-3 levels in idiopathic sudden sensorineural hearing loss. Increased plasma ESM-1 levels may confirm endothelial dysfunction involvement in idiopathic sudden sensorineural hearing loss pathogenesis, which could be associated with vascular impairment.

Keywords

Hearing Loss, SuddenEndotheliumVascular Endothelial Cells
Type
Main Articles
Information
The Journal of Laryngology & Otology , Volume 132 , Issue 11 , November 2018 , pp. 995 - 999
Copyright
Copyright © JLO (1984) Limited, 2018 

Access options

Get access to the full version of this content by using one of the access options below. (Log in options will check for institutional or personal access. Content may require purchase if you do not have access.)

Footnotes

Dr A Bayram takes responsibility for the integrity of the content of the paper

Presented at the 39th Turkish National Congress of Otolaryngology Head and Neck Surgery, 8–12 November 2017, Antalya, Turkey.

References

1Stachler, RJ, Chandrasekhar, SS, Archer, SM, Rosenfeld, RM, Schwartz, SR, Barrs, DM et al. Clinical practice guideline: sudden hearing loss. Otolaryngol Head Neck Surg 2012;146:1–35Google Scholar
2Byl, FM Jr. Sudden hearing loss: eight years’ experience and suggested prognostic table. Laryngoscope 1984;94:647–61Google Scholar
3Kuhn, M, Heman-Ackah, SE, Shaikh, JA, Roehm, PC. Sudden sensorineural hearing loss: a review of diagnosis, treatment, and prognosis. Trends Amplif 2011;15:91–105Google Scholar
4Conlin, AE, Parnes, LS. Treatment of sudden sensorineural hearing loss: I. A systematic review. Arch Otolaryngol Head Neck Surg 2007;133:573–81Google Scholar
5Chau, JK, Lin, JR, Atashband, S, Irvine, RA, Westerberg, BD. Systematic review of the evidence for the etiology of adult sudden sensorineural hearing loss. Laryngoscope 2010;120:1011–21Google Scholar
6Mattox, DE, Simmons, FB. Natural history of sudden sensorineural hearing loss. Ann Otol Rhinol Laryngol 1977;86:463–80Google Scholar
7Quaranta, N, De Ceglie, V, D'Elia, A. Endothelial dysfunction in idiopathic sudden sensorineural hearing loss: a review. Audiol Res 2016;6:151Google Scholar
8Lassalle, P, Molet, S, Janin, A, Heyden, JV, Tavernier, J, Fiers, W et al. ESM-1 is a novel human endothelial cell-specific molecule expressed in lung and regulated by cytokines. J Biol Chem 1996;271:20458–64Google Scholar
9Yang, WE, Hsieh, MJ, Lin, CW, Kuo, CY, Yang, SF, Chuang, CY et al. Plasma levels of endothelial cell-specific molecule-1 as a potential biomarker of oral cancer progression. Int J Med Sci 2017;14:1094–100Google Scholar
10Balta, I, Balta, S, Koryurek, OM, Demirkol, S, Mikhailidis, DP, Celik, T et al. Serum endocan levels as a marker of disease activity in patients with Behçet disease. J Am Acad Dermatol 2014;70:291–6Google Scholar
11Balta, I, Balta, S, Demirkol, S, Mikhailidis, DP, Celik, T, Akhan, M et al. Elevated serum levels of endocan in patients with psoriasis vulgaris: correlations with cardiovascular risk and activity of disease. Br J Dermatol 2013;169:1066–70Google Scholar
12Yilmaz, MI, Siriopol, D, Saglam, M, Kurt, YG, Unal, HU, Eyileten, T et al. Plasma endocan levels associate with inflammation, vascular abnormalities, cardiovascular events, and survival in chronic kidney disease. Kidney Int 2014;86:1213–20Google Scholar
13Mantovani, A, Garlanda, C, Bottazzi, B, Peri, G, Doni, A, Martinez de la Torre, Y et al. The long pentraxin PTX3 in vascular pathology. Vascul Pharmacol 2006;45:326–30Google Scholar
14Yasunaga, T, Ikeda, S, Koga, S, Nakata, T, Yoshida, T, Masuda, N et al. Plasma pentraxin 3 is a more potent predictor of endothelial dysfunction than high-sensitive C-reactive protein. Int Heart J 2014;55:160–4Google Scholar
15Liu, S, Qu, X, Liu, F, Wang, C. Pentraxin 3 as a prognostic biomarker in patients with systemic inflammation or infection. Mediators Inflamm 2014;2014:421429Google Scholar
16World Health Organization. International Classification of Impairments, Disabilities and Handicaps. Geneva: World Health Organization, 1980;73Google Scholar
17Siegel, LG. The treatment of idiopathic sudden sensorineural hearing loss. Otolaryngol Clin North Am 1975;8:467–73Google Scholar
18Li, P, Zeng, XL, Ye, J, Yang, QT, Zhang, GH, Li, Y. Intratympanic methylprednisolone improves hearing function in refractory sudden sensorineural hearing loss: a control study. Audiol Neurootol 2011;16:198–202Google Scholar
19Nakagawa, T, Yamamoto, M, Kumakawa, K, Usami, S, Hato, N, Tabuchi, K et al. Prognostic impact of salvage treatment on hearing recovery in patients with sudden sensorineural hearing loss refractory to systemic corticosteroids: a retrospective observational study. Auris Nasus Larynx 2016;43:489–94Google Scholar
20Dai, Y, Lu, L, Hou, J, Yang, X, Li, H, Yang, Y et al. Intratympanic methylprednisolone perfusion as a salvage treatment for profound idiopathic sudden sensorineural hearing loss. J Laryngol Otol 2017;131:404–10Google Scholar
21Pezzoli, M, Magnano, M, Maffi, L, Pezzoli, L, Marcato, P, Orione, M et al. Hyperbaric oxygen therapy as salvage treatment for sudden sensorineural hearing loss: a prospective controlled study. Eur Arch Otorhinolaryngol 2015;272:1659–66Google Scholar
22Quaranta, N, Ramunni, A, De Luca, C, Brescia, P, Dambra, P, De Tullio, G et al. Endothelial progenitor cells in sudden sensorineural hearing loss. Acta Otolaryngol 2011;131:347–50Google Scholar
23Capaccio, P, Pignataro, L, Gaini, LM, Sigismund, PE, Novembrino, C, De Giuseppe, R et al. Unbalanced oxidative status in idiopathic sudden sensorineural hearing loss. Eur Arch Otorhinolaryngol 2012;269:449–53Google Scholar
24Gul, F, Muderris, T, Yalciner, G, Sevil, E, Bercin, S, Ergin, M et al. A comprehensive study of oxidative stress in sudden hearing loss. Eur Arch Otorhinolaryngol 2017;274:1301–8Google Scholar
25Quaranta, N, Ramunni, A, Brescia, P, D'Elia, A, Vacca, A, Ria, R. Soluble intercellular adhesion molecule 1 and soluble vascular cell adhesion molecule 1 in sudden hearing loss. Otol Neurotol 2008;29:470–4Google Scholar
26Ciccone, MM, Cortese, F, Pinto, M, Di Teo, C, Fornarelli, F, Gesualdo, M et al. Endothelial function and cardiovascular risk in patients with idiopathic sudden sensorineural hearing loss. Atherosclerosis 2012;225:511–16Google Scholar
27Berjis, N, Moeinimehr, M, Hashemi, SM, Hashemi, SM, Bakhtiari, EK, Nasiri, S. Endothelial dysfunction in patients with sudden sensorineural hearing loss. Adv Biomed Res 2016;5:5Google Scholar
28Kanbay, A, Ceylan, E, İnönü Köseoğlu, H, Çalışkan, M, Takir, M, Tulu, S et al. Endocan: a novel predictor of endothelial dysfunction in obstructive sleep apnea syndrome. Clin Respir J 2018;12:84–90Google Scholar
29Hamad, RR, Eriksson, MJ, Berg, E, Larsson, A, Bremme, K. Impaired endothelial function and elevated levels of pentraxin 3 in early-onset preeclampsia. Acta Obstet Gynecol Scand 2012;91:50–6Google Scholar
30Witasp, A, Ryden, M, Carrero, JJ, Qureshi, AR, Nordfors, L, Näslund, E et al. Elevated circulating levels and tissue expression of pentraxin 3 in uremia: a reflection of endothelial dysfunction. PLoS One 2013;8:e63493Google Scholar
31Tong, M, Carrero, JJ, Qureshi, AR, Anderstam, B, Heimbürger, O, Bárány, P et al. Plasma pentraxin 3 in patients with chronic kidney disease: associations with renal function, protein-energy wasting, cardiovascular disease, and mortality. Clin J Am Soc Nephrol 2007;2:889–97Google Scholar
32Suliman, ME, Yilmaz, MI, Carrero, JJ, Qureshi, AR, Saglam, M, Ipcioglu, OM et al. Novel links between the long pentraxin 3, endothelial dysfunction, and albuminuria in early and advanced chronic kidney disease. Clin J Am Soc Nephrol 2008;3:976–85Google Scholar